D3 BIO
D3 Bio is a globally focused biotechnology company focusing on developing and registration of innovative medicines in oncology and immunology. At D3 Bio, our new medicine development approach is fundamentally differentiated. We do not just only start with science in the lab. First, we pinpoint the greatest unmet patient and market needs – where existing standard-of-care approaches yield unsatisfactory clinical outcomes. Then we take those insights into the lab to guide the identification of fit for purpose science and technology and define our drug development path.
D3 BIO
Industry:
Biotechnology Life Science Pharmaceutical
Founded:
2014-01-01
Address:
Shangai, Jiangxi, China
Country:
China
Website Url:
http://www.d3bio.com
Status:
Active
Total Funding:
200 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics Domain Not Resolving
Similar Organizations
Antengene Corporation
Antengene is a developer of biotechnology and bio-pharmaceuticals intended to provide medicine treatment for tumor.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Current Employees Featured
Founder
Investors List
Sequoia Capital China
Sequoia Capital China investment in Series A - D3 Bio
Boyu Capital
Boyu Capital investment in Series A - D3 Bio
WuXi AppTec
WuXi AppTec investment in Series A - D3 Bio
Matrix Partners China
Matrix Partners China investment in Series A - D3 Bio
Temasek Holdings
Temasek Holdings investment in Series A - D3 Bio
Official Site Inspections
http://www.d3bio.com
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 75.2.70.75
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "D3 Bio"
D3 Bio appoints Dr. Antoine Yver as Independent Board Member
Mar 8, 2024 He currently serves as Chairman of Development at Centessa Pharmaceuticals and as independent director on the board of Sanofi SA. Dr. Yver is also Founder of ‘The Blue …See details»
D3 Bio Company Profile 2024: Valuation, Funding & Investors
Nov 19, 2020 D3 Bio General Information Description. Developer of biotechnology focused on the development and innovation of drugs in oncology and immunology. The company focuses …See details»
D3 Bio Received IND Clearance from FDA to Initiate Phase I …
Medicxi Announces $40m investment in D3 Bio | Medicxi
Apr 8, 2024 Medicxi Announces $40m investment in D3 Bio · Investment will support development of a differentiated pipeline in oncology · Most advanced asset is D3S-001 with …See details»
D3 Bio Company Profile - Office Locations, Competitors, Revenue …
D3 Bio $200 m in total funding,. See insights on D3 Bio including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
D3 Bio Completes Series A+ Round to Advance Innovative …
Apr 8, 2024 For more information please visit: www.d3bio.com. About Medicxi Medicxi is a healthcare-focused investment firm with the mission to create and invest in companies across …See details»
D3 Bio Completes Series A+ Round to Advance Innovative …
Apr 8, 2024 D3 Bio, an emerging global biotechnology company that focuses on discovery, development, and registration of innovative cancer drugs announces its closing of Series A+ …See details»
Ex-AstraZeneca executive launches D3 Bio with $200M
Nov 17, 2020 D3 Bio has emerged with $200 million from a syndicate of heavy hitters and an ex-AstraZeneca leader in the CEO role. George Chen, M.D., set up D3 Bio after seven years at …See details»
D3 Bio Launches with $200 Million to Advance Precision Medicine …
O n November 17th, global biotech D3 Bio launched with a $200 million Series A financing by Boyu Capital, Matrix Partners China, Wuxi AppTech, Temasek, and Sequoia. The funding will …See details»
D3 Bio Completes Series A+ Round to Advance Innovative …
Apr 8, 2024 The substantial investment of US$62M in this round underscores D3 Bio's steadfast commitment to advancing its pioneering oncology pipeline. The funding will be allocated to …See details»
D3 Bio Launches with US$200 Million Investment to Develop …
Nov 17, 2020 D3 Bio, launched today with US $200 million Series A financing, which will support the development of D3 Bio’s portfolio in oncology and immunology.See details»
D3 Bio’s D3S-001 Demonstrates Significantly Improved
Nov 25, 2024 D3 Bio’s D3S-001 Demonstrates Significantly Improved Covalent Potency in Depleting Cellular Active KRAS in Pre-Clinical and Clinical Studies in KRAS G12C-Mediated …See details»
D3 Bio Announces Data Presentations at the Society for …
Shanghai, China—D3 Bio (Wuxi) Co. Ltd (“D3 Bio” or “Company”), a biotechnology company that focuses on discovery, development, and registration of innovative medicines in the fields of …See details»
D3 Bio’s D3S-001 Demonstrates Significantly Improved Covalent …
SHANGHAI, November 25, 2024--D3 Bio, a global clinical stage biotechnology company focusing on discovery, development, and registration of innovative cancer drugs, announced that its …See details»
D3 Bio Completes $62 Million Series A+ - Cooley
Shanghai – April 8, 2024 – Cooley advised D3 Bio, an emerging global biotechnology company that focuses on discovery, development and registration of innovative cancer drugs, on the …See details»
D3 Bio Announces Receiving an Orphan Drug Designation and …
Mar 31, 2023 Shanghai, China—D3 Bio (Wuxi) Co. Ltd (“D3 Bio” or “Company”), a biotechnology company that focuses on discovery, development, and registration of innovative medicines in …See details»
D3 Bio Announces Clinical Data Presentations at the 2024 AACR …
Shanghai, China, April 1, 2024 — D3 Bio announced the forthcoming presentations of new preclinical research and clinical trial data from its oncology program, D3S-001, at the 2024 …See details»
D3 Bio Announces Oral Presentation of the Clinical Data of Its Lead ...
Shanghai, China, September 12, 2024 — D3 Bio, a global biotechnology company that focuses on discovery, development, and registration of innovative cancer drugs, announced that it will …See details»